WEKO3
アイテム
{"_buckets": {"deposit": "d65e5114-8a56-4039-b72f-cf78bf236087"}, "_deposit": {"created_by": 6, "id": "27374", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "27374"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00027374", "sets": ["7"]}, "author_link": ["121787", "121786", "121788", "121785", "121784"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-03-12", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "106826", "bibliographicVolumeNumber": "116", "bibliographic_titles": [{"bibliographic_title": "Leukemia Research"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Primary effusion lymphoma (PEL) is an aggressive B-cell non-Hodgkin lymphoma in immunocompromised in-dividuals such as AIDS patients. PEL shows a poor prognosis (median survival time \u003c 6 months) compared with other AIDS-related lymphomas, and is generally resistant to conventional treatments. Novel drugs for PEL treatment are required. Midkine inhibitor (iMDK) was previously found to suppress midkine protein expression. Interestingly, iMDK suppressed cell proliferation in PEL cell lines in a time- and dose-dependent manner, regardless of midkine gene expression. We examined the mechanism of iMDK on PEL. Importantly, iMDK strongly induced cell cycle arrest at the G2/M phase within 12 h of incubation and suppressed the p-CDK1 protein level, which is associated with the cell cycle checkpoint at G2/M, resulting in mitotic catastrophe with observation of multipolar division. After mitotic catastrophe, iMDK-treated PEL showed apoptosis with caspase-3, 8, and 9 activation at 24 h incubation. However, iMDK showed no effects on viral protein-activated signaling pathways such as JAK-STAT, PI3K-Akt and NF-κB, and HHV-8/KSHV gene expression in PEL. These results indicate that iMDK is a novel CDK1 inhibitor and a promising lead compound for PEL chemotherapy treatment.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Leukemia Research, 116, art. no. 106826; 2022", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Ltd"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.leukres.2022.106826", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2022 Elsevier Ltd. All rights reserved."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "01452126", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ueno, Mikinori"}], "nameIdentifiers": [{"nameIdentifier": "121784", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kariya, Ryusho"}], "nameIdentifiers": [{"nameIdentifier": "121785", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Gunya, Sittithumcharee"}], "nameIdentifiers": [{"nameIdentifier": "121786", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Cheevapruk, Kodcharat"}], "nameIdentifiers": [{"nameIdentifier": "121787", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okada, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "121788", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2023-03-12"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "LR116_106826.pdf", "filesize": [{"value": "2.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2000000.0, "url": {"label": "LR116_106826.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/27374/files/LR116_106826.pdf"}, "version_id": "95b098e0-8264-4b08-a800-55f8a2594e80"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Primary effusion lymphoma (PEL)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Midkine inhibitor (iMDK)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Apoptosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cell cycle", "subitem_subject_scheme": "Other"}, {"subitem_subject": "AIDS", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest"}]}, "item_type_id": "2", "owner": "6", "path": ["7"], "permalink_uri": "http://hdl.handle.net/10069/00041512", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-05-13"}, "publish_date": "2022-05-13", "publish_status": "0", "recid": "27374", "relation": {}, "relation_version_is_last": true, "title": ["Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest"], "weko_shared_id": -1}
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest
http://hdl.handle.net/10069/00041512
http://hdl.handle.net/10069/00041512249d0efa-9611-4e76-8344-7eae81daffa4
名前 / ファイル | ライセンス | アクション |
---|---|---|
LR116_106826.pdf (2.0 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-05-13 | |||||
タイトル | ||||||
タイトル | Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Primary effusion lymphoma (PEL) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Midkine inhibitor (iMDK) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Apoptosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cell cycle | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | AIDS | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ueno, Mikinori
× Ueno, Mikinori× Kariya, Ryusho× Gunya, Sittithumcharee× Cheevapruk, Kodcharat× Okada, Seiji |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Primary effusion lymphoma (PEL) is an aggressive B-cell non-Hodgkin lymphoma in immunocompromised in-dividuals such as AIDS patients. PEL shows a poor prognosis (median survival time < 6 months) compared with other AIDS-related lymphomas, and is generally resistant to conventional treatments. Novel drugs for PEL treatment are required. Midkine inhibitor (iMDK) was previously found to suppress midkine protein expression. Interestingly, iMDK suppressed cell proliferation in PEL cell lines in a time- and dose-dependent manner, regardless of midkine gene expression. We examined the mechanism of iMDK on PEL. Importantly, iMDK strongly induced cell cycle arrest at the G2/M phase within 12 h of incubation and suppressed the p-CDK1 protein level, which is associated with the cell cycle checkpoint at G2/M, resulting in mitotic catastrophe with observation of multipolar division. After mitotic catastrophe, iMDK-treated PEL showed apoptosis with caspase-3, 8, and 9 activation at 24 h incubation. However, iMDK showed no effects on viral protein-activated signaling pathways such as JAK-STAT, PI3K-Akt and NF-κB, and HHV-8/KSHV gene expression in PEL. These results indicate that iMDK is a novel CDK1 inhibitor and a promising lead compound for PEL chemotherapy treatment. | |||||
書誌情報 |
Leukemia Research 巻 116, p. 106826, 発行日 2022-03-12 |
|||||
出版者 | ||||||
出版者 | Elsevier Ltd | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 01452126 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.leukres.2022.106826 | |||||
権利 | ||||||
権利情報 | © 2022 Elsevier Ltd. All rights reserved. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Leukemia Research, 116, art. no. 106826; 2022 |